Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies

In patients with primary antibody deficiencies, subcutaneous administration of IgG (SCIG) replacement is effective, safe, well-tolerated, and can be self-administered at home. A new SCIG replacement at 20% concentration (Hizentra(®)) has been developed and has replaced Vivaglobin(®) (SCIG 16%). An o...

Descripción completa

Detalles Bibliográficos
Autores principales: Canessa, Clementina, Iacopelli, Jessica, Pecoraro, Antonio, Spadaro, Giuseppe, Matucci, Andrea, Milito, Cinzia, Vultaggio, Alessandra, Agostini, Carlo, Cinetto, Francesco, Danieli, Maria Giovanna, Gambini, Simona, Marasco, Carolina, Trizzino, Antonino, Vacca, Angelo, De Mattia, Domenico, Martire, Baldassarre, Plebani, Alessandro, Di Gioacchino, Mario, Gatta, Alessia, Finocchi, Andrea, Licciardi, Francesco, Martino, Silvana, De Carli, Marco, Moschese, Viviana, Azzari, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806788/
https://www.ncbi.nlm.nih.gov/pubmed/27927705
http://dx.doi.org/10.1177/0394632016681577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806788/
https://www.ncbi.nlm.nih.gov/pubmed/27927705
http://dx.doi.org/10.1177/0394632016681577

Ejemplares similares